Literature DB >> 2119299

Usefulness of an aura for classification of a first generalized seizure.

C A van Donselaar1, A T Geerts, R J Schimsheimer.   

Abstract

In 67 of 149 patients with a generalized first seizure, the occurrence of some kind of sensation immediately preceding the loss of consciousness was the only clue that possibly indicated focal onset of the seizure. We studied the interobserver agreement between six neurologists regarding the interpretation of these preceding feelings as either a nonspecific symptom or an aura implicating a focal onset of the seizure. The observers also classified the seizures as generalized from onset, undetermined, or partial secondarily generalized. To assess the accuracy of the classification, we obtained a standard EEG, an EEG after partial sleep deprivation, a computed tomography (CT) scan, and a follow-up report after 1 year. The subclassification on clinical grounds of a generalized first seizure is too unreliable and probably too invalid as well to be useful in clinical practice or in epidemiologic research.

Entities:  

Mesh:

Year:  1990        PMID: 2119299     DOI: 10.1111/j.1528-1157.1990.tb06102.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  4 in total

1.  Auras Are Frequent in Patients With Generalized Epilepsy.

Authors:  David Spencer
Journal:  Epilepsy Curr       Date:  2015 Mar-Apr       Impact factor: 7.500

2.  [Commentary on the guidelines the diagnosis and the therapy of syncope--the European Society of Cardiology 2001 and the update 2004].

Authors:  K Seidl; A Schuchert; J Tebbenjohanns; W Hartung
Journal:  Z Kardiol       Date:  2005-09

3.  Idiopathic first seizure in adult life: who should be treated?

Authors:  C A van Donselaar; A T Geerts; R J Schimsheimer
Journal:  BMJ       Date:  1991-03-16

Review 4.  A guide to disorders causing transient loss of consciousness: focus on syncope.

Authors:  J Gert van Dijk; Roland D Thijs; David G Benditt; Wouter Wieling
Journal:  Nat Rev Neurol       Date:  2009-07-14       Impact factor: 42.937

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.